Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35654052

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Jun
First author
Kater AP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jun;23(6):699-701. doi: 10.1016/S1470-2045(22)00266-2.
    note
    Source null
    related pmid
    35654051
    relationship
    Comment in

Authors and identifiers

  1. name
    Kater AP
    type
    Author
  2. name
    Levin MD
    type
    Author
  3. name
    Dubois J
    type
    Author
  4. name
    Kersting S
    type
    Author
  5. name
    Enggaard L
    type
    Author
  6. name
    Veldhuis GJ
    type
    Author
  7. name
    Mous R
    type
    Author
  8. name
    Mellink CHM
    type
    Author
  9. name
    van der Kevie-Kersemaekers AF
    type
    Author
  10. name
    Dobber JA
    type
    Author
  11. name
    Poulsen CB
    type
    Author
  12. name
    Frederiksen H
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kater AP
    type
    Author
  2. name
    Levin MD
    type
    Author
  3. name
    Dubois J
    type
    Author
  4. name
    Kersting S
    type
    Author
  5. name
    Enggaard L
    type
    Author
  6. name
    Veldhuis GJ
    type
    Author
  7. name
    Mous R
    type
    Author
  8. name
    Mellink CHM
    type
    Author
  9. name
    van der Kevie-Kersemaekers AF
    type
    Author
  10. name
    Dobber JA
    type
    Author
  11. name
    Poulsen CB
    type
    Author
  12. name
    Frederiksen H
    type
    Author
bibliography ids
  1. nci-bib-60e6db2260fc2e53eec570e9
book metadata
content sha256
35eae4b87ceaf574543e257526633e5101a414f7c2703389b8abaf3cc58bb272
document type
citation
dois
  1. 10.1016/S1470-2045(22)00220-0
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35654052
immutable id
pubmed:35654052@35eae4b87ceaf574543e257526633e5101a414f7c2703389b8abaf3cc58bb272
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
818-828
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jun;23(6):699-701. doi: 10.1016/S1470-2045(22)00266-2.
    note
    Source null
    related pmid
    35654051
    relationship
    Comment in
outcomes validated
false
pmid
35654052
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
ece0d75d67befe1d15df88d95de412a20e347647e58f1a3dcfe2b2e536f159ab
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Jun
precision
month
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35654052/
title
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Preserved source evidence · Not medical advice